Celltrion Reports Positive Rheumatoid Arthritis Data From Subcutaneous Infliximab

 
• By Akriti Seth

New data presented by Celltrion at EULAR 2019 suggest that its subcutaneous formulation of infliximab is comparable to the intravenous version in treating rheumatoid arthritis.

Hands_Arthritis
Celltrion’s subcutaneous formulation of infliximab is comparable to the intravenous version in rheumatoid arthritis • Source: Shutterstock

Celltrion Healthcare’s new subcutaneous (SC) formulation of its CT-P13 biosimilar infliximab has shown positive results for the treatment of rheumatoid arthritis (RA) compared to the intravenous version, according to the firm’s latest data.

At this year’s European Congress of Rheumatology, EULAR, the South Korean firm presented a two-part study investigating the pharmacokinetics, efficacy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products